Egfr mutations

Abstract

The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

1 .- 39 . (canceled) 
     
     
         40 . A method for treating an individual having a non-small cell lung cancer (NSCLC) tumor, wherein the cells of said tumor comprise nucleic acid that encodes an EGFR protein mutation; wherein said EGFR protein mutation is G719A, E746K, S768I, L858P, or E746-R748 del; and wherein said method comprises administering an EGFR inhibitor appropriate for the treatment of said tumor to said individual. 
     
     
         41 . The method of  claim 40 , wherein said nucleic acid encoding said EGFR protein mutation is detected by amplifying the nucleic acid region corresponding to said EGFR protein mutation in an EGFR gene and comparing the electrophoretic mobility of the amplified nucleic acid to the electrophoretic mobility of the corresponding region in a wild-type EGFR gene. 
     
     
         42 . The method of  claim 40 , wherein said nucleic acid encoding said EGFR protein mutation is detected by amplifying the nucleic acid region corresponding to said EGFR protein mutation in an EGFR gene and sequencing said amplified nucleic acid. 
     
     
         43 . The method of  claim 40 , wherein the presence of said nucleic acid encoding said EGFR protein mutation is detected by allele-specific polymerase chain reaction. 
     
     
         44 . The method of  claim 40 , wherein said EGFR protein mutation is G719A. 
     
     
         45 . The method of  claim 40 , wherein said EGFR protein mutation is E746K. 
     
     
         46 . The method of  claim 40 , wherein said EGFR protein mutation is S768I. 
     
     
         47 . The method of  claim 40 , wherein said EGFR protein mutation is L858P. 
     
     
         48 . The method of  claim 40 , wherein said EGFR protein mutation is E746-R748 del. 
     
     
         49 . The method of  claim 40 , wherein said method further comprises administration of a chemotherapeutic agent. 
     
     
         50 . The method of  claim 49 , wherein said EGFR protein mutation is G719A. 
     
     
         51 . The method of  claim 49 , wherein said EGFR protein mutation is E746K. 
     
     
         52 . The method of  claim 49 , wherein said EGFR protein mutation is S768I. 
     
     
         53 . The method of  claim 49 , wherein said EGFR protein mutation is L858P. 
     
     
         54 . The method of  claim 49 , wherein said EGFR protein mutation is E746-R748 del.